NEPTUNE, N.J.--(BUSINESS WIRE)--Excelsior Medical Corporation announced today that it has received FDA 510(k) clearance for SwabFlush™, its latest product for the vascular access and infection control ...
Stage-Specific Outcomes of Patients With Uterine Leiomyosarcoma: A Comparison of the International Federation of Gynecology and Obstetrics and American Joint Committee on Cancer Staging Systems During ...
DefenCath is intended for instillation into central venous catheters only. DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--According to the CDC, considerable progress is being made in preventing central line associated blood stream infections, but further improvement is still needed. An ...
April 5, 2005 — The European Commission has approved for use in the European Union a second-generation embolic protection system for use in saphenous vein graft interventional procedures; the Japanese ...
Great Lakes Pharmaceuticals Inc. has agreed to an exclusive worldwide license of intellectual property developed at the University of Texas M.D. Anderson Cancer Center and Wake Forest University ...
The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
The FDA approved a taurolidine and heparin (DefenCath) catheter lock solution for reducing the risk of bloodstream infections in patients on dialysis. Approved under a special limited agency pathway, ...
SwabFlush combines SwabCap and the ZR Catheter Flush Syringe into one device, to make it easier for nurses to flush, disinfect and protect the IV connector all at the same time. (Photo: Business Wire) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results